SCHEMBL4201192

SCHEMBL4201192

COc1ccc(-c2cncc(NCc3cnc4ccccc4c3)c2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.50
PDGFRA P16234 3/20 0.50
PDE10A Q9Y233 7/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
PIK3CD O00329 1/20 0.49
PIK3CA P42336 1/20 0.49
PIK3CB P42338 1/20 0.49
MTOR P42345 1/20 0.49
PIK3CG P48736 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
NFKB1 P19838 1/20 0.49
HTT P42858 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194226 0.84 CYP1A2 (0.55) PDGFRBPDGFRANPC1RAB9APIK3CD
SCHEMBL4189065 0.81 ALDH1A1 (0.56) RAB9AKDM4EALDH1A1LMNAGAA
SCHEMBL4187245 0.80 CYP2A6 (0.60) PDGFRBPDGFRANPC1RAB9AKDM4E
SCHEMBL4184437 0.78 ALPL (0.51) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL29377512 0.77 PIK3CD (0.73) PDGFRBPDGFRANPC1RAB9APIK3CD
SCHEMBL4191284 0.77 CYP1A2 (0.49) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL4187421 0.77 BRAF (0.54) NPC1RAB9AKDM4EGAASMN1; SMN2
SCHEMBL4189975 0.77 FYN (0.55) PDGFRBPDGFRAKDM4EALDH1A1LMNA
SCHEMBL4187573 0.76 FYN (0.61) PIK3CAKDM4EALDH1A1LMNAGAA
SCHEMBL4180512 0.76 KCNH2 (0.51) PDGFRBPDGFRAKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 PDGFRB 4237/4885PDGFRA 4611/4885PDE10A 1904/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 PDGFRB 4237/4885PDGFRA 4611/4885PDE10A 1904/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 PDGFRB 4237/4885PDGFRA 4611/4885PDE10A 1904/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA PDGFRB 614/4885PDGFRA 550/4885PDE10A 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.